{"id":841599,"date":"2026-10-14T16:57:02","date_gmt":"2026-10-14T16:57:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=841599"},"modified":"2026-10-14T16:57:02","modified_gmt":"2026-10-14T16:57:02","slug":"myotonic-dystrophy-clinical-trial-drug-development-pipeline-expands-with-contributions-from-20-key-companies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myotonic-dystrophy-clinical-trial-drug-development-pipeline-expands-with-contributions-from-20-key-companies-delveinsight_841599.html","title":{"rendered":"Myotonic Dystrophy Clinical Trial Drug Development Pipeline Expands with Contributions from 20+ Key Companies | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1791970181.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Myotonic Dystrophy Clinical Trial Drug Development Pipeline Expands with Contributions from 20+ Key Companies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1791970181.jpg\" alt=\"Myotonic Dystrophy Clinical Trial Drug Development Pipeline Expands with Contributions from 20+ Key Companies | DelveInsight\" width=\"225\" height=\"118\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Myotonic Dystrophy Clinical trial analysis report delivers important insights into ongoing research on 20+ pipeline Myotonic Dystrophy drugs, clinical strategies, upcoming therapeutics, and commercial analysis.<\/div>\n<p style=\"text-align: justify;\"><strong>(Albany, US) On October 14, 2026 &#8211; <\/strong>DelveInsight&rsquo;s, &ldquo;<strong>Myotonic Dystrophy Pipeline Insight 2026<\/strong>&rdquo; report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Myotonic Dystrophy pipeline landscape. It covers the Myotonic Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myotonic Dystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Stay ahead with the latest insights! Download DelveInsight&rsquo;s comprehensive Myotonic Dystrophy Pipeline Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myotonic-dystrophy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/myotonic-dystrophy-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Myotonic Dystrophy Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>On September 29, 2026 &ndash; Dyne Therapeutics<\/em><\/strong> announced that its investigational therapy, zeleciment basivarsen (DYNE-101), demonstrated improvements across multiple functional measures in the Phase 1\/2 ACHIEVE trial for Myotonic Dystrophy Type 1 (DM1). The company expects topline data from the registrational expansion cohort in the first quarter of 2027.<\/li>\n<li><strong><em>On September 08, 2026 &ndash; Novartis<\/em><\/strong> announced that delpacibart etedesiran (del-desiran) did not achieve the primary endpoint in the Phase III HARBOR study. However, the company reported signals of clinical activity in secondary endpoints and exploratory analyses and stated that it would assess the complete dataset to determine the appropriate development path.<\/li>\n<li>DelveInsight&rsquo;s Myotonic Dystrophy pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myotonic Dystrophy treatment.<\/li>\n<li>The leading Myotonic Dystrophy Companies such as <strong><em>AMO Pharma, Lupin, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Pepgen Corporation, Aparito<\/em><\/strong> and others.<\/li>\n<li>Promising Myotonic Dystrophy Pipeline Therapies such as <strong><em>AOC 1001, Mexiletine, PGN-EDODM1, SomatoKine\/IPLEX, AOC 1001 (del-desiran), Tideglusib, ATX-01<\/em><\/strong> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Access DelveInsight&rsquo;s in-depth Pipeline Analysis for a closer look at promising breakthroughs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myotonic-dystrophy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Myotonic Dystrophy Clinical Trials and Studies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Myotonic Dystrophy Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Myotonic dystrophy is a chronic, progressive, autosomal dominant disorder characterized by muscle weakness and myotonia, which refers to the delayed relaxation of muscles after contraction. There are two major forms recognized based on clinical and molecular presentation: Myotonic dystrophy type I (DM1), known as Steinert disease, and myotonic dystrophy type II (DM2), or proximal myotonic myopathy which is a milder variety of DMI. These are progressive, multisystem genetic disorders. Clinical presentation is diverse and can range from asymptomatic electrical myotonia to severe weakness and disability, including cardiac conduction defects, infertility, cataracts, and insulin resistance.<\/p>\n<p style=\"text-align: justify;\"><strong>Myotonic Dystrophy Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Del-desiran (AOC 1001): Novartis AG<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Del-desiran, utilizing Avidity&#8217;s AOC platform technology, is designed to address the underlying genetic cause of DM1 by reducing levels of toxic DMPK mRNA. Del-desiran consists of a proprietary monoclonal antibody that binds to transferrin receptor 1 (TfR1) and is conjugated to a siRNA that targets DMPK mRNA. Del-desiran has received Breakthrough Therapy, Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA) and Orphan designation by the European Medicines Agency (EMA). Del-desiran was also the first investigational treatment for DM1 to receive Orphan Drug designation in Japan. This drug was developed by Avidity Biosciences which has been fully acquired by Novartis AG. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Myotonic Dystrophy.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ARO-DM1: Arrowhead Pharmaceuticals, Inc.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ARO-DM1 is an RNA interference (RNAi) conjugate designed to specifically silence DMPK mRNA in skeletal muscle and the silencing of aberrantly transcribed DMPK mRNA using ARO-DM1 may halt CUGexp-related spliceopathies in patients with DM1 leading to improved muscle strength and function. This drug belongs to a class of medicines called RNA therapeutics. Preclinical data shows ARO-DM1 achieved greater than 80% silencing of DMPK in skeletal muscle, which was maintained for longer than 85 days. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Myotonic Dystrophy.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ATX-01: Arthex Biotech<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ATX-01 is an antimiR oligonucleotide designed to target microRNA 23b(miR-23b), which is involved in the pathogenesis of DM1. It has been demonstrated, in human DM1 myoblast cell lines and in two murine models, that ATX-01 has a unique, dual mechanism of action which reduces toxic DMPK mRNA and increases MBNL protein production. ATX-01 was discovered through ARTHEx&rsquo;s in-house discovery engine, which was built to identify, design and optimize novel gene expression modulators and ensure their preferential delivery to target tissues affected by the disease. Currently, the drug is being evaluated in the Phase I\/II stage of its development for the treatment of Myotonic Dystrophy.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>SAR446268: Sanofi<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">SAR446268 employs a vectorized RNA interference (RNAi) approach to silence DMPK expression through a single administration. By reducing DMPK transcripts, the gene therapy aims to eliminate the abnormal and toxic RNA foci responsible for splicing defects in muscle tissue, thereby restoring normal splicing and improving muscular function. This approach has the potential to address key symptoms of the disease, including progressive muscle weakness, difficulty relaxing muscles (myotonia), and effects on multiple body systems including heart, lungs, and endocrine functions. The US Food and Drug Administration (FDA) has granted fast track designation to SAR446268 in September 2025. Currently, the drug is being evaluated in the Phase I\/II stage of its development for the treatment of Myotonic Dystrophy.<\/p>\n<p style=\"text-align: justify;\"><strong>The Myotonic Dystrophy pipeline report provides insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Myotonic Dystrophy with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myotonic Dystrophy Treatment.<\/li>\n<li>Myotonic Dystrophy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Myotonic Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myotonic Dystrophy market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get a detailed analysis of the latest innovations in the Myotonic Dystrophy pipeline. Explore DelveInsight&rsquo;s expert-driven report today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myotonic-dystrophy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Myotonic Dystrophy Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Myotonic Dystrophy Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>AMO Pharma, Lupin, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Pepgen Corporation, Aparito<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\"><strong>The Myotonic Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intra-articular<\/li>\n<li>Intraocular<\/li>\n<li>Intrathecal<\/li>\n<li>Intravenous<\/li>\n<li>Ophthalmic<\/li>\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<li>Transdermal<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Myotonic Dystrophy Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oligonucleotide<\/li>\n<li>Peptide<\/li>\n<li>Small molecule<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download DelveInsight&rsquo;s latest report to gain strategic insights into upcoming Myotonic Dystrophy Therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myotonic-dystrophy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Myotonic Dystrophy Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Myotonic Dystrophy Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Myotonic Dystrophy Companies- <strong><em>AMO Pharma, Lupin, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Pepgen Corporation, Aparito<\/em><\/strong> and others.<\/li>\n<li>Myotonic Dystrophy Pipeline Therapies- <strong><em>AOC 1001, Mexiletine, PGN-EDODM1, SomatoKine\/IPLEX, AOC 1001 (del-desiran), Tideglusib, ATX-01<\/em><\/strong> and others.<\/li>\n<li>Myotonic Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Myotonic Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Which companies are leading the race in Myotonic Dystrophy drug development? @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myotonic-dystrophy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Myotonic Dystrophy Emerging Drugs and Major Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Myotonic Dystrophy: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Myotonic Dystrophy&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Mexiletine: Lupin<\/li>\n<li>Mid-Stage Products (Phase II)<\/li>\n<li>Pitolisant: Harmony Biosciences<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>Comparative Analysis<\/li>\n<li>ARO-DM1: Arrowhead Pharmaceuticals, Inc.<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Inactive Products<\/li>\n<li>Myotonic Dystrophy Key Companies<\/li>\n<li>Myotonic Dystrophy Key Products<\/li>\n<li>Myotonic Dystrophy- Unmet Needs<\/li>\n<li>Myotonic Dystrophy- Market Drivers and Barriers<\/li>\n<li>Myotonic Dystrophy- Future Perspectives and Conclusion<\/li>\n<li>Myotonic Dystrophy Analyst Views<\/li>\n<li>Myotonic Dystrophy Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=myotonic-dystrophy-clinical-trial-drug-development-pipeline-expands-with-contributions-from-20-key-companies-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/myotonic-dystrophy-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/myotonic-dystrophy-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=myotonic-dystrophy-clinical-trial-drug-development-pipeline-expands-with-contributions-from-20-key-companies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Myotonic Dystrophy Clinical trial analysis report delivers important insights into ongoing research on 20+ pipeline Myotonic Dystrophy drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 14, 2026 &#8211; DelveInsight&rsquo;s, &ldquo;Myotonic Dystrophy Pipeline Insight 2026&rdquo; report &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/myotonic-dystrophy-clinical-trial-drug-development-pipeline-expands-with-contributions-from-20-key-companies-delveinsight_841599.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-841599","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/841599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=841599"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/841599\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=841599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=841599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=841599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}